La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

3SBio Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Jing Lou

Directeur général

CN¥4.9m

Rémunération totale

Pourcentage du salaire du PDG	26.2%
Durée du mandat du directeur général	17.9yrs
Propriété du PDG	2.2%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	6.2yrs

Mises à jour récentes de la gestion

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

Recent updates

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Analyse de la rémunération des PDG

Comment la rémunération de Jing Lou a-t-elle évolué par rapport aux bénéfices de 3SBio?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Dec 31 2023	CN¥5m	CN¥1m	CN¥2b
Sep 30 2023	n/a	n/a	CN¥2b
Jun 30 2023	n/a	n/a	CN¥2b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	CN¥4m	CN¥1m	CN¥2b
Sep 30 2022	n/a	n/a	CN¥2b
Jun 30 2022	n/a	n/a	CN¥2b
Mar 31 2022	n/a	n/a	CN¥2b
Dec 31 2021	CN¥4m	CN¥932k	CN¥2b
Sep 30 2021	n/a	n/a	CN¥1b
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥934m
Dec 31 2020	CN¥4m	CN¥432k	CN¥836m
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥194m	CN¥432k	CN¥974m
Sep 30 2019	n/a	n/a	CN¥1b
Jun 30 2019	n/a	n/a	CN¥1b
Mar 31 2019	n/a	n/a	CN¥1b
Dec 31 2018	CN¥6m	CN¥432k	CN¥1b
Sep 30 2018	n/a	n/a	CN¥1b
Jun 30 2018	n/a	n/a	CN¥1b
Mar 31 2018	n/a	n/a	CN¥996m
Dec 31 2017	CN¥5m	CN¥432k	CN¥935m

Rémunération vs marché: La rémunération totale de Jing ($USD 685.96K ) est dans la moyenne des entreprises de taille similaire sur le marché Hong Kong ($USD 629.60K ).

Rémunération et revenus: La rémunération de Jing a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Jing Lou (61 yo)

17.9yrs

Titularisation

CN¥4,896,000

Compensation

Dr. Jing Lou, M.D., Ph.D. is a Co-Founder of 3SBio Inc. and has been its Executive Chairman of the Board since April 1, 2012 and also serves as its Chief Executive Officer and President. Dr. Lou is Directo...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Jing Lou	Co-Founder	17.9yrs	CN¥4.90m	2.17% CN¥ 329.8m
Dongmei Su	Senior VP & Executive Director	12.2yrs	CN¥1.47m	1.04% CN¥ 157.0m
Tianruo Pu	Independent Non-Executive Director	9.2yrs	CN¥270.00k	pas de données
Jiaoe Zhang	Non-Executive Director	less than a year	pas de données	0.55% CN¥ 83.1m
Hoi Ti Yang	Independent Non-Executive Director	3.2yrs	CN¥270.00k	pas de données
Joo Yeow Ng	Independent Non-Executive Director	2.6yrs	CN¥270.00k	pas de données

6.2yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 1530 sont considérés comme expérimentés (ancienneté moyenne 6.2 ans).

3SBio Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

3Sbio Inc. Announces Management Changes

3SBio Inc., Annual General Meeting, Jun 25, 2024

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

Recent updates

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly